Table 3.
The monotherapy survival rates recorded in articles on patients.
| Study | Year | Media first response | Media PFS | Media follow-up | ORR |
|---|---|---|---|---|---|
| Roberts AW | 2016 | 6 weeks (5–24) | 25 months (17–30) | 17 months (1–44) | 79% |
| Coutre S | 2018 | 2.5 months (1.6–8.1) | NM | 14 months (1–29) | 67% |
| Jones JA | 2018 | 2.5 months (1.6–2.6) | 24.7 months (19.2–NT) | 14 months (8–18) | 65% |
| Stilgenbauer S | 2016 | 0.8 months (0.7–1.7) | 6.3 months (4.8–9.8) | 12.1 months (10.1–14.2) | 79.4% |
| Kumar S | 2017 | 9.7 months (7.0–NT) | 2.6 months (1.9–4.7) | 2.5 months (0.2–25) | 21% |
| Konopleva M | 2016 | 144.5 days (83–256) | 2.5 months (1–3) | 63.5 days (14–256) | 19% |
| Davids MS | 2017 | 42 days (30–366) | 6 months (4–10) | 5.3 months (0.2–46.0) | 44% |
NT, not reached; PFS, progression-free survival; NM, not mentioned; ORR, overall response rate.